The M17/4 antibody reacts with the 180 kDa αL chain of LFA-1 (CD11a/CD18, αLβ2 integrin), a heterodimeric surface glycoprotein
expressed on almost all leukocytes. CD8a+CD8b- intestinal intraepithelial T lymphocytes, which are believed to be thymus independent, do
not express CD11a. LFA-1 mediates a variety of heterotypic and homotypic intercellular adhesions through interaction with ICAM-1 (CD54)
and ICAM-2 (CD102), including participation in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells.
mAb M17/4 blocks a variety of LFA-1-mediated cells interactions in vitro, and costimulatory effects have also been described. In vivo
treatment with M17/4 mAb reduces the severity of graft-versus-host reactions, prolongs allograft survival, inhibits the development of
autoimmunity, and blocks substance P-induced leukocyte migration. The M17/4 and 2D7 (Cat. No. 553120) antibodies are reported to
recognize different epitopes of the CD11a molecule.
注意事项：
1.Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2.Store undiluted at 4°C.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
